GlassScriptPhysician profile
Danielle Marie Orsini
NPI 1306286018
$1,990.95
in general payments reported to CMS, 2019-2025
13 companies · $658 in 2025
The $658 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $271 · 2023: $499 · 2024: $437 · 2025: $658.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.54 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,426.68 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $150.24 | 2021-2025 | Fasenra |
| Amgen INC. | $112.77 | 2025 | Tezspire |
| Grifols USA, LLC | $61.46 | 2023-2025 | Prolastin-C Liquid |
| Verona Pharma, INC. | $49.60 | 2025 | Ohtuvayre |
| Pulmonx Corporation | $41.52 | 2022 | |
| Inspire Medical Systems, INC. | $25.05 | 2023 | Inspire |
| Astellas Pharma US INC | $24.72 | 2023 | Cresemba |
| Genzyme Corporation | $22.94 | 2023 | |
| Lilly USA, LLC | $22.37 | 2025 | Zepbound |
| Regeneron Healthcare Solutions, INC. | $22.20 | 2023 | Dupixent |
| Pfizer INC. | $16.11 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Orsini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.